Placeholder Banner

Dr. Moncef Slaoui “Excellent Choice” to Lead Operation Warp Speed

May 13, 2020
Media Contact
Author-Profile-Andrew-Segerman

Following the announcement that Dr. Moncef Slaoui will lead the Trump Administration's "Operation Warp Speed" initiative, BIO’s President and CEO, Jim Greenwood, issued the following statement: 

“Dr. Moncef Slaoui is an excellent choice to lead the President’s Operation Warp Speed initiative. Over his long career, he has demonstrated a strong commitment to public health, innovation and a public-private partnership that are vital to building the collaborations we need to bring new therapeutics, diagnostics and vaccines to the American people. Dr. Slaoui has always stood for scientific excellence, and the biotechnology industry stands ready to work with him as we begin this new effort in the race to eradicate the pandemic.”

###

Discover More
Immunologist Michelle McMurry-Heath is Selected  for Her Global Leadership and Commitment to Innovation and Patients Former FDA Official Will…
The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by…
Today, the Centers for Medicare and Medicaid Services announced that it is proposing to create a new Medicare-severity-diagnosis related group (MS-DRG) designed specifically for reimbursing providers administering CAR T-cell therapies to cancer…